Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS Chronic liver injury often results in activation of hepatic myofibroblasts and development of liver fibrosis. Hepatic myofibroblasts may originate from three major sources; Hepatic Stellate Cells (HSCs), Portal Fibroblasts (PFs), or fibrocytes. Their contribution to liver fibrosis varies dependent on the etiology of liver injury. Here we assessed the composition of hepatic myofibroblasts in multidrug resistance gene 2 knockout (Mdr2-/-) mice, a genetic model that resembles primary sclerosing cholangitis in patients. METHODS Mdr2-/- mice expressing a collagen-GFP reporter were analyzed at different ages. Hepatic nonparenchymal cells isolated from collagen-GFP Mdr2-/- mice were sorted based on collagen-GFP and vitamin A. A nicotinamide adenine dinucleotide phosphate oxidase (NOX) 1/4 inhibitor was administrated to Mdr2-/- mice during ages 12- to 16-weeks-old to assess the therapeutic approach targeting oxidative stress in cholestatic injury. RESULTS Thy1+ activated PFs (aPFs) accounted for 26%, 51%, and 54% of collagen-GFP+ myofibroblasts in Mdr2-/- mice at 4 weeks, 8 weeks, and 16 weeks of age, respectively. The remaining collagen-GFP+ myofibroblasts were composed of activated HSCs (aHSCs), suggesting that PFs and HSCs are both activated in Mdr2-/- mice. BM-derived fibrocytes minimally contributed to liver fibrosis in Mdr2-/- mice. Development of cholestatic liver fibrosis in Mdr2-/- mice was associated with early recruitment of Gr1+ myeloid cells and upregulation of pro-inflammatory cytokines (4 weeks). Administration of a NOX inhibitor to 12-week-old Mdr2-/- mice suppressed activation of myofibroblasts and attenuated development of cholestatic fibrosis. CONCLUSIONS aPFs and aHSCs contribute to cholestatic fibrosis in Mdr2-/- mice, and serve as targets for anti-fibrotic therapy. LAY SUMMARY Activated Portal Fibroblasts and Hepatic Stellate Cells, but not fibrocytes, contributed to the production of the fibrous scar in livers of Mdr2-/- mice, and these cells can serve as targets for anti-fibrotic therapy in cholestatic injury. Therapeutic inhibition of the enzyme nicotinamide adenine dinucleotide phosphate oxidase (NOX) in Mdr2-/- mice reversed cholestatic fibrosis, suggesting that targeting of NOXs can provide a novel strategy for treatment of cholestatic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Self-citationOrigin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535
Self-citationBaghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.024 · Cited by 187
Liu, L., & Gudas, L. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509643200 · Cited by 181
Bettaieb, A., Jiang, J. X., Sasaki, Y., Chao, T.-I., Kiss, Z., Chen, X., Tian, J., Katsuyama, M., Yabe-Nishimura, C., Xi, Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.009 · Cited by 167
Origin and function of myofibroblasts in the liver
Schwabe, R., & Wells, R. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550061 · Cited by 86
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Self-citationYang, W., He, H., Wang, T., Su, N., Zhang, F., Jiang, K., Zhu, J., Zhang, C., Niu, K., Wang, L., et al. (2021) · Hepatology · doi:10.1002/hep.31987 · Cited by 250
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
“In the multidrug resistance gene 2 knockout (Mdr2−/−) mice spontaneously developing cholestatic fibrosis, fibrocytes only minimally contributed to the deposition of ECM in the injured livers (Nishio et al., 2019).”
BackgroundAkkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“However, both activated HSCs and portal fibroblasts promote cholestatic liver fibrosis caused by periportal injury [43,44].”
BackgroundResultHeterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Self-citation
Metadata
- Authors
- Nishio, T., Hu, R., Koyama, Y., Liang, S., Rosenthal, S. B., Yamamoto, G., Karin, D., Baglieri, J., Ma, H.-Y., Xu, J., Liu, X., Dhar, D., Iwaisako, K., Taura, K., Brenner, D. A., & Kisseleva, T.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 71
- Issue
- 3
- Pages
- 573-585
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2943334785
- Cited by
- 135
- References
- 10
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. https://app.cochat.ai/papers/10.1016/j.jhep.2019.04.012
- The paper
- Nishio, T., Hu, R., Koyama, Y., Liang, S., Rosenthal, S. B., Yamamoto, G., Karin, D., Baglieri, J., Ma, H.-Y., Xu, J., Liu, X., Dhar, D., Iwaisako, K., Taura, K., Brenner, D. A., & Kisseleva, T. (2019). Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.04.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.